You don’t see something until you have the right metaphor to let you perceive it”? James Gleick
Today, we look at a small biopharma concern that had a big insider buy within a secondary offering toward the end of last year by a company director. A full analysis follows in the paragraphs below in this week’s "deep dive."
Company Overview:
Exicure (XCUR) is a Skokie, Ill.,-based early-stage biopharmaceutical concern focused on leveraging its Spherical Nucleic Acid ((SNA)) technology to treat inflammatory, oncological, and genetic disorders. The company has tested three compounds in